litlas
ログインアカウント作成

Richard Kefford

1982–2021 年に発表

144
論文数
43,614
被引用数
100
h 指数
143
i10 指数

被引用数

Richard Kefford の年別被引用数1982 年: 被引用 2 件1983 年: 被引用 2 件1986 年: 被引用 3 件1987 年: 被引用 3 件1988 年: 被引用 5 件1989 年: 被引用 7 件1990 年: 被引用 14 件1991 年: 被引用 14 件1992 年: 被引用 10 件1993 年: 被引用 16 件1994 年: 被引用 15 件1995 年: 被引用 19 件1996 年: 被引用 11 件1997 年: 被引用 18 件1998 年: 被引用 20 件1999 年: 被引用 34 件2000 年: 被引用 23 件2001 年: 被引用 30 件2002 年: 被引用 35 件2003 年: 被引用 33 件2004 年: 被引用 33 件2005 年: 被引用 36 件2006 年: 被引用 41 件2007 年: 被引用 31 件2008 年: 被引用 48 件2009 年: 被引用 89 件2010 年: 被引用 97 件2011 年: 被引用 155 件2012 年: 被引用 348 件2013 年: 被引用 626 件2014 年: 被引用 933 件2015 年: 被引用 1,035 件2016 年: 被引用 861 件2017 年: 被引用 957 件2018 年: 被引用 859 件2019 年: 被引用 2,226 件2020 年: 被引用 2,113 件2021 年: 被引用 1,681 件2022 年: 被引用 1,299 件2023 年: 被引用 885 件2024 年: 被引用 1,175 件2025 年: 被引用 479 件2026 年: 被引用 8 件1984〜1985 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,963 件、この内訳の 27.7%中国: 引用元論文 1,694 件、この内訳の 9.5%イギリス: 引用元論文 1,071 件、この内訳の 6%イタリア: 引用元論文 1,005 件、この内訳の 5.6%オーストラリア: 引用元論文 987 件、この内訳の 5.5%ドイツ: 引用元論文 986 件、この内訳の 5.5%フランス: 引用元論文 875 件、この内訳の 4.9%オランダ: 引用元論文 619 件、この内訳の 3.5%カナダ: 引用元論文 527 件、この内訳の 2.9%スペイン: 引用元論文 499 件、この内訳の 2.8%スイス: 引用元論文 472 件、この内訳の 2.6%日本: 引用元論文 430 件、この内訳の 2.4%
0%27.7%その他 21.1%

機関

分野

  • Medicine56.9%
  • Biochemistry, Genetics and Molecular Biology32.5%
  • Immunology and Microbiology6.3%
  • Engineering0.8%
  • Computer Science0.7%
  • Nursing0.5%
  • その他2.3%

トピック

  • Cancer Immunotherapy and Biomarkers12.9%
  • Melanoma and MAPK Pathways8.5%
  • Immunotherapy and Immune Responses6.2%
  • Cutaneous Melanoma Detection and Management5.5%
  • CAR-T cell therapy research5.3%
  • Cancer Genomics and Diagnostics3.3%
  • その他58.3%

共著者

全論文

検索で開く
  1. Whole-genome landscapes of major melanoma subtypes

    著者: Nicholas K. Hayward, James S. Wilmott, Nicola Waddell, Peter A. Johansson, Matthew A. Field, Kátia Nones, Ann‐Marie Patch, Hojabr Kakavand, Ludmil B. Alexandrov, Hazel Burke, Valerie Jakrot, Stephen H. Kazakoff, Oliver Holmes, Conrad Leonard, Radhakrishnan Sabarinathan, Loris Mularoni, Scott Wood, Qinying Xu, Nick M. Waddell, Varsha Tembe, Gulietta M. Pupo, Ricardo De Paoli‐Iseppi, Ricardo E. Vilain, Ping Shang, Loretta M. S. Lau, Rebecca A. Dagg, Sarah‐Jane Schramm, Antonia L. Pritchard, Ken Dutton‐Regester, Felicity Newell, Anna Fitzgerald, Catherine A. Shang, Sean M. Grimmond, Hilda A. Pickett, Jean Yang, Jonathan R. Stretch, Andreas Behren, Richard Kefford, Peter Hersey, Georgina V. Long, Jonathan Cebon, Mark Shackleton, Andrew J. Spillane, Robyn P.M. Saw, Núria López-Bigas, John V. Pearson, John F. Thompson, Richard A. Scolyer, Graham J. Mann - Nature 2017 被引用: 1,522

  2. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

    著者: Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen‐Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Mitchell, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Qi Zhao, E. Jensen, S. Ahsan, Nageatte Ibrahim, Antoni Ribas - Annals of Oncology 2019 被引用: 944

  3. Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

    著者: Steven O’Day, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Richard Kefford, Jean‐Jacques Grob, Laurent Mortier, Caroline Robert, Jacob Schachter, Alessandro Testori, Jacek Mackiewicz, Philip Friedlander, Claus Garbe, Selma Ugurel, Frances A. Collichio, Wei Guo, Joelle Lufkin, Safi R. Bahcall, Vojo Vukovic, Axel Hauschild - Journal of Clinical Oncology 2013 被引用: 386

  4. Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated Melanoma

    著者: Georgina V. Long, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion‐Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Caroline Robert, Laurent Mortier, Jacob Schachter, Dirk Schadendorf, Thierry Lesimple, Ruth Plummer, Ran Ji, Pingkuan Zhang, Bijoyesh Mookerjee, Jeff Legos, Richard Kefford, Reinhard Dummer, John M. Kirkwood - New England Journal of Medicine 2017 被引用: 1,475

  5. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    著者: Omid Hamid, Caroline Robert, Adil Daud, F. Stephen Hodi, Wen-Jen Hwu, Richard Kefford, Jedd D. Wolchok, Peter Hersey, Richard W. Joseph, Jeffrey S. Weber, Roxana Dronca, Tara C. Gangadhar, Amita Patnaik, Hassane M. Zarour, Anthony M. Joshua, Kevin Gergich, Jeroen Elassaiss‐Schaap, Alain P. Algazi, Christine Mateus, Peter D. Boasberg, Paul C. Tumeh, Bartosz Chmielowski, Scot Ebbinghaus, Xiaoyun Li, Sunyu Kang, Antoni Ribas - New England Journal of Medicine 2013 被引用: 3,395

  6. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    著者: Keith T. Flaherty, J. Infante, Adil Daud, René González, Richard Kefford, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Igor Puzanov, Peter F. Lebowitz, Ajay P. Singh, Shonda M Little, Peng Sun, Alicia J. Allred, Danièle Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey S. Weber - New England Journal of Medicine 2012 被引用: 2,798

  7. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

    著者: Antoni Ribas, Omid Hamid, Adil Daud, F. Stephen Hodi, Jedd D. Wolchok, Richard Kefford, Anthony M. Joshua, Amita Patnaik, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Peter Hersey, Roxana Dronca, Richard W. Joseph, Hassane M. Zarour, Bartosz Chmielowski, Donald P. Lawrence, Alain P. Algazi, Naiyer A. Rizvi, Brianna Hoffner, Christine Mateus, Kevin Gergich, Jill A. Lindia, Maxine Giannotti, Xiaoyun Li, Scot Ebbinghaus, Soonmo Peter Kang, Caroline Robert - JAMA 2016 被引用: 1,062

  8. Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

    著者: Jenny Lee, Elena Shklovskaya, Su Yin Lim, Matteo S. Carlino, Alexander M. Menzies, Ashleigh Stewart, Bernadette Pedersen, Malama Irvine, Sara Alavi, Jean Yang, Dario Strbenac, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Georgina V. Long, Richard Kefford, Helen Rizos - Nature Communications 2020 被引用: 303

  9. Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

    著者: Adil Daud, Jedd D. Wolchok, Caroline Robert, Wen-Jen Hwu, Jeffrey S. Weber, Antoni Ribas, F. Stephen Hodi, Anthony M. Joshua, Richard Kefford, Peter Hersey, Richard W. Joseph, Tara C. Gangadhar, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Charlotte Roach, Grant Toland, Jared Lunceford, Xiaoyun Li, Kenneth Emancipator, Marisa Dolled‐Filhart, Sunyu Kang, Scot Ebbinghaus, Omid Hamid - Journal of Clinical Oncology 2016 被引用: 678

  10. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

    著者: Caroline Robert, Antoni Ribas, Jedd D. Wolchok, F. Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S. Weber, Anthony M. Joshua, Wen-Jen Hwu, Tara C. Gangadhar, Amita Patnaik, Roxana Dronca, Hassane M. Zarour, Richard W. Joseph, Peter D. Boasberg, Bartosz Chmielowski, Christine Mateus, Michael A. Postow, Kevin Gergich, Jeroen Elassaiss‐Schaap, Xiaoyun Li, Robert Iannone, Scot Ebbinghaus, Soonmo Peter Kang, Adil Daud - The Lancet 2014 被引用: 1,761

  11. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    著者: Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, René González, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Peter Hersey, Richard Kefford, Donald P. Lawrence, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, K. B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas - New England Journal of Medicine 2012 被引用: 2,148

  12. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

    著者: Hubing Shi, Willy Hugo, Xiangju Kong, Aayoung Hong, Richard C. Koya, Gatien Moriceau, Thinle Chodon, Rongqing Guo, Douglas B. Johnson, Kimberly B. Dahlman, Mark C. Kelley, Richard Kefford, Bartosz Chmielowski, John A. Glaspy, Jeffrey A. Sosman, Nicolas van Baren, Georgina V. Long, Antoni Ribas, Roger S. Lo - Cancer Discovery 2013 被引用: 986

  13. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

    著者: Caroline Robert, Antoni Ribas, Omid Hamid, Adil Daud, Jedd D. Wolchok, Anthony M. Joshua, Wen-Jen Hwu, Jeffrey S. Weber, Tara C. Gangadhar, Richard W. Joseph, Roxana Dronca, Amita Patnaik, Hassane M. Zarour, Richard Kefford, Peter Hersey, Jin Zhang, James R. Anderson, Scott J. Diede, Scot Ebbinghaus, F. Stephen Hodi - Journal of Clinical Oncology 2017 被引用: 482

  14. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

    著者: Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford - The Lancet 2012 被引用: 933

  15. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies

    著者: Jenny Lee, Georgina V. Long, Alexander M. Menzies, Serigne Lo, Alexander Guminski, Kataraina Whitbourne, Michelle Peranec, Richard A. Scolyer, Richard Kefford, Helen Rizos, Matteo S. Carlino - JAMA Oncology 2018 被引用: 311

  16. BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

    著者: Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, Richard Kefford, Richard A. Scolyer, Georgina V. Long - Clinical Cancer Research 2014 被引用: 542

  17. Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    著者: Antoni Ribas, Richard Kefford, Margaret Marshall, Cornelis J.A. Punt, John B.A.G. Haanen, Maribel Mármol, Claus Garbe, Helen Gogas, Jacob Schachter, Gerald P. Linette, Paul Lorigan, Kari Kendra, Michele Maio, Uwe Trefzer, Michael Smylie, Grant A. McArthur, Brigitte Dréno, Paul Nathan, Jacek Mackiewicz, John M. Kirkwood, Jesús Gómez-Navarro, Bo Huang, Dmitri Pavlov, Axel Hauschild - Journal of Clinical Oncology 2013 被引用: 815

  18. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

    著者: Georgina V. Long, Alexander M. Menzies, Adnan Nagrial, Lauren E. Haydu, Anne Hamilton, Graham J. Mann, Michael Hughes, John F. Thompson, Richard A. Scolyer, Richard Kefford - Journal of Clinical Oncology 2011 被引用: 1,047

  19. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

    著者: Douglas B. Johnson, Alexander M. Menzies, Lisa Zimmer, Zeynep Eroglu, Fei Ye, Shilin Zhao, Helen Rizos, Antje Sucker, Richard A. Scolyer, Ralf Gutzmer, Helen Gogas, Richard Kefford, John F. Thompson, Jürgen C. Becker, Carola Berking, Friederike Egberts, Carmen Loquai, Simone M. Goldinger, Gulietta M. Pupo, Willy Hugo, Xiangju Kong, Levi A. Garraway, Jeffrey A. Sosman, Antoni Ribas, Roger S. Lo, Georgina V. Long, Dirk Schadendorf - European Journal of Cancer 2015 被引用: 330

  20. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial

    著者: Georgina V. Long, Robyn P.M. Saw, Serigne Lo, Omgo E. Nieweg, Kerwin F. Shannon, Maria Gonzalez, Alexander Guminski, Jenny Lee, Hansol Lee, Peter M. Ferguson, Robert V. Rawson, James S. Wilmott, John F. Thompson, Richard Kefford, Sydney Ch’ng, Jonathan R. Stretch, Louise Emmett, Rony Kapoor, Helen Rizos, Andrew J. Spillane, Richard A. Scolyer, Alexander M. Menzies - The Lancet Oncology 2019 被引用: 185

  21. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

    著者: Georgina V. Long, Carina Fung, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Jessica Hyman, Hamideh Shahheydari, Varsha Tembe, John F. Thompson, Robyn P.M. Saw, Julie R. Howle, Nicholas K. Hayward, Peter A. Johansson, Richard A. Scolyer, Richard Kefford, Helen Rizos - Nature Communications 2014 被引用: 387

  22. Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

    著者: James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa Sharma, John F. Thompson, Richard Kefford, Peter Hersey, Richard A. Scolyer - Clinical Cancer Research 2011 被引用: 650

  23. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

    著者: Richard W. Joseph, Jeroen Elassaiss‐Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D. Wolchok, Anthony M. Joshua, Antoni Ribas, F. Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S. Weber, Amita Patnaik, Dinesh P. de Alwis, Andrea Perrone, Jin Zhang, Soonmo Peter Kang, Scot Ebbinghaus, Keaven M. Anderson, Tara C. Gangadhar - Clinical Cancer Research 2018 被引用: 309

  24. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

    著者: Jenny Lee, Robyn P.M. Saw, John F. Thompson, Serigne Lo, Andrew J. Spillane, Kerwin F. Shannon, Jonathan R. Stretch, Julie R. Howle, Alexander M. Menzies, Matteo S. Carlino, Richard Kefford, Georgina V. Long, Richard A. Scolyer, Helen Rizos - Annals of Oncology 2019 被引用: 112